MicroRNA-519d targets MKi67 and suppresses cell growth in the hepatocellular carcinoma cell line QGY-7703

Cancer Letters

Volumn 307, Issue 2, 2011, Pages 182-190

  Hou, Yan Yan ^a   Cao, Wei Wei ^a   Li, Lan ^a   Li, Sheng Ping ^b   Liu, Tao ^a   Wan, Hai Ying ^a   Liu, Min ^a   Li, Xin ^a   Tang, Hua ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; MicroRNA; MiR 519d; MKi67; QGY 7703

Indexed keywords

MICRORNA; MICRORNA 519D; UNCLASSIFIED DRUG;

ARTICLE; BIOINFORMATICS; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MKI67 GENE; PRIORITY JOURNAL;

BASE SEQUENCE; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA PRIMERS; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MICRORNAS; NUCLEAR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79957649751     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.04.002     Document Type: Article

References (43)

1. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
2. Liu T., Tang H., Lang Y., Liu M., Li X. MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett. 2009, 273:233-242.
3. Moriyama T., Ohuchida K., Mizumoto K., Yu J., Sato N., Nabae T., Takahata S., Toma H., Nagai E., Tanaka M. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol. Cancer Ther. 2009, 4528-4538.
4. Selbach M., Schwanhausser B., Thierfelder N., Fang Z., Khanin R., Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008, 455:58-63.
5. Tay Y., Zhang J., Thomson A.M., Lim B., Rigoutsos I. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008, 455:1124-1128.
6. Chi S.W., Zang J.B., Mele A., Darnell R.B. Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 2009, 460:479-486.
7. Calin G.A., Sevignani C., Dumitru C.D., Hyslop T., Noch E., Yendamuri S., Shimizu M., Rattan S., Bullrich F., Negrini M., Croce C.M. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA 2004, 101:2999-3004.
8. Zhang L., Huang J., Yang N., Greshock J., Megraw M.S., Giannakakis A., Liang S., Naylor T.L., Barchetti A., Ward M.R., Yao G., Medina A., O'Brien-Jenkins A., Katsaros D., Hatzigeorgiou A., Gimotty P.A., Weber B.L., Coukos G. MicroRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl. Acad. Sci. USA 2006, 103:9136-9141.
9. Iorio M.V., Visone R., Di Leva G., Donati V., Petrocca F., Casalini P., Taccioli C., Volinia S., Liu C.G., Alder H., Calin G.A., Menard S., Croce C.M. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007, 67:8699-8707.
10. Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., Stephens R.M., Okamoto A., Yokota J., Tanaka T., Calin G.A., Liu C.G., Croce C.M., Harris C.C. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
11. Iorio M.V., Ferracin M., Liu C.G., Veronese A., Spizzo R., Sabbioni S., Magri E., Pedriali M., Fabbri M., Campiglio M., Menard S., Palazzo J.P., Rosenberg A., Musiani P., Volinia S., Nenci I., Calin G.A., Querzoli P., Negrini M., Croce C.M. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65:7065-7070.
12. Chan J.A., Krichevsky A.M., Kosik K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005, 65:6029-6033.
13. Wan H.Y., Guo L.M., Liu T., Liu M., Li X., Tang H. Regulation of the transcription factor NF-kappaB1 by microRNA-9 in human gastric adenocarcinoma. Mol. Cancer 2010, 9:16.
14. Furuta M., Kozaki K.I., Tanaka S., Arii S., Imoto I., Inazawa J. MiR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010, 31:766-776.
15. Chung G.E., Yoon J.H., Myung S.J., Lee J.H., Lee S.H., Lee S.M., Kim S.J., Hwang S.Y., Lee H.S., Kim C.Y. High expression of microRNA-15b predicts a low risk of tumor recurrence following curative resection of hepatocellular carcinoma. Oncol. Rep. 2010, 23:113-119.
16. Barshack I., Meiri E., Rosenwald S., Lebanony D., Bronfeld M., Aviel-Ronen S., Rosenblatt K., Polak-Charcon S., Leizerman I., Ezagouri M., Zepeniuk M., Shabes N., Cohen L., Tabak S., Cohen D., Bentwich Z., Rosenfeld N. Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression. Int. J. Biochem. Cell Biol. 2010, 42:1355-1362.
17. Shigoka M., Tsuchida A., Matsudo T., Nagakawa Y., Saito H., Suzuki Y., Aoki T., Murakami Y., Toyoda H., Kumada T., Bartenschlager R., Kato N., Ikeda M., Takashina T., Tanaka M., Suzuki R., Oikawa K., Takanashi M., Kuroda M. Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol. Int. 2010, 60:351-357.
18. Wong Q.W., Ching A.K., Chan A.W., Choy K.W., To K.F., Lai P.B., Wong N. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin. Cancer Res. 2010, 16:867-875.
19. Gramantieri L., Fornari F., Callegari E., Sabbioni S., Lanza G., Croce C.M., Bolondi L., Negrini M. MicroRNA involvement in hepatocellular carcinoma. J. Cell Mol. Med. 2008, 12:2189-2204.
20. Wang Y., Lee A.T., Ma J.Z., Wang J., Ren J., Yang Y., Tantoso E., Li K.B., Ooi L.L., Tan P., Lee C.G. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J. Biol. Chem. 2008, 283:13205-13215.
21. Fornari F., Milazzo M., Chieco P., Negrini M., Calin G.A., Grazi G.L., Pollutri D., Croce C.M., Bolondi L., Gramantieri L. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2010, 70:5184-5193.
22. Liu C., Yu J., Yu S., Lavker R.M., Cai L., Liu W., Yang K., He X., Chen S. MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma. J. Hepatol. 2010, 53:98-107.
23. Starborg M., Gell K., Brundell E., Hoog C. The murine Ki-67 cell proliferation antigen accumulates in the nucleolar and heterochromatic regions of interphase cells and at the periphery of the mitotic chromosomes in a process essential for cell cycle progression. J. Cell Sci. 1996, 109(Pt 1):143-153.
24. Smallridge R.C., Marlow L.A., Copland J.A. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr. Relat. Cancer 2009, 16:17-44.
25. Griffiths E.A., Pritchard S.A., McGrath S.M., Valentine H.R., Price P.M., Welch I.M., West C.M. Hypoxia-associated markers in gastric carcinogenesis and HIF-2alpha in gastric and gastro-oesophageal cancer prognosis. Br. J. Cancer 2008, 98:965-973.
26. von Minckwitz G., Sinn H.P., Raab G., Loibl S., Blohmer J.U., Eidtmann H., Hilfrich J., Merkle E., Jackisch C., Costa S.D., Caputo A., Kaufmann M. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res. 2008, 10:R30.
27. du Manoir S., Guillaud P., Camus E., Seigneurin D., Brugal G. Ki-67 labeling in postmitotic cells defines different Ki-67 pathways within the 2c compartment. Cytometry 1991, 12:455-463.
28. Preusser M., Heinzl H., Gelpi E., Hoftberger R., Fischer I., Pipp I., Milenkovic I., Wohrer A., Popovici F., Wolfsberger S., Hainfellner J.A. Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Histopathology 2008, 53:39-47.
29. Kuo K.T., Chang H.C., Hsiao C.H., Lin M.C. Increased Ki-67 proliferative index and absence of P16INK4 in CIN-HPV related pathogenic pathways different from cervical squamous intraepithelial lesion. Br. J. Ophthalmol. 2006, 90:894-899.
30. Settakorn J., Kaewpila N., Burns G.F., Leong A.S., FAT E-cadherin, beta catenin, HER 2/neu, Ki67 immuno-expression, and histological grade in intrahepatic cholangiocarcinoma. J. Clin. Pathol. 2005, 58:1249-1254.
31. Cheah P.L., Looi L.M., Nazarina A.R., Mun K.S., Goh K.L. Association of Ki67 with raised transaminases in hepatocellular carcinoma. Malays. J. Pathol. 2008, 30:103-107.
32. Kikuchi M., Mikami T., Sato T., Tokuyama W., Araki K., Watanabe M., Saigenji K., Okayasu I. High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction. Br. J. Cancer 2009, 101:116-123.
33. Kloosterman W.P., Plasterk R.H. The diverse functions of microRNAs in animal development and disease. Dev. Cell 2006, 11:441-450.
34. Abdelmohsen K., Srikantan S., Kuwano Y., Gorospe M. miR-519 reduces cell proliferation by lowering RNA-binding protein HuR levels. Proc. Natl. Acad. Sci. USA 2008, 105:20297-20302.
35. Wersto R.P., Herz F., Gallagher R.E., Koss L.G. Cell cycle-dependent reactivity with the monoclonal antibody Ki-67 during myeloid cell differentiation. Exp. Cell Res. 1988, 179:79-88.
36. van Dekken H., Verhoef C., Wink J., van Marion R., Vissers K.J., Hop W.C., de Man R.A., JN I.J., van Eijck C.H., Zondervan P.E. Cell biological evaluation of liver cell carcinoma, dysplasia and adenoma by tissue micro-array analysis. Acta. Histochem. 2005, 107:161-171.
37. Scholzen T., Gerdes J. The Ki-67 protein: from the known and the unknown. J. Cell Physiol. 2000, 182:311-322.
38. Rahrmann E.P., Collier L.S., Knutson T.P., Doyal M.E., Kuslak S.L., Green L.E., Malinowski R.L., Roethe L., Akagi K., Waknitz M., Huang W., Largaespada D.A., Marker P.C. Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen. Cancer Res. 2009, 69:4388-4397.
39. Di Vizio D., Demichelis F., Simonetti S., Pettinato G., Terracciano L., Tornillo L., Freeman M.R., Insabato L. Skp2 expression is associated with high risk and elevated Ki67 expression in gastrointestinal stromal tumours. BMC Cancer 2008, 8:134.
40. Mizobuchi H., Garcia-Castellano J.M., Philip S., Healey J.H., Gorlick R. Hypoxia markers in human osteosarcoma: an exploratory study. Clin. Orthop. Relat. Res. 2008, 466:2052-2059.
41. Khor L.Y., Bae K., Paulus R., Al-Saleem T., Hammond M.E., Grignon D.J., Che M., Venkatesan V., Byhardt R.W., Rotman M., Hanks G.E., Sandler H.M., Pollack A. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. J. Clin. Oncol. 2009, 27:3177-3184.
42. Nigro J.M., Baker S.J., Preisinger A.C., Jessup J.M., Hostetter R., Cleary K., Bigner S.H., Davidson N., Baylin S., Devilee P., et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989, 342:705-708.
43. Santisteban M., Reynolds C., Barr Fritcher E.G., Frost M.H., Vierkant R.A., Anderson S.S., Degnim A.C., Visscher D.W., Pankratz V.S., Hartmann L.C. Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia. Breast Cancer Res. Treat. 2009, 121:431-437.